Try a new search

Format these results:

Searched for:

person:bogenm02

in-biosketch:true

Total Results:

130


Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder

Gold, Noah D; Pagni, Broc A; Petridis, Petros D; Bogenschutz, Michael P
BACKGROUND/UNASSIGNED:Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed relationships between value changes, acute psilocybin experiences, and drinking outcomes. METHODS/UNASSIGNED:-tests. Pearson correlations examined the relationship between value changes and acute effects, and also value changes and drinking outcomes. RESULTS/UNASSIGNED:= 0.31). None of the value changes were significantly associated with drinking outcomes. CONCLUSION/UNASSIGNED:PAT may alter value structure in patients with AUD patients by increasing Conservation. Although some associations were found between acute psychedelic effects and changes in Conservation, these value changes were not related to drinking outcomes.
PMCID:12054612
PMID: 40337752
ISSN: 2831-4433
CID: 5839352

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research

Yaden, David B; Graziosi, Marianna; Owen, Alexa M; Agin-Liebes, Gabrielle; Aaronson, Scott T; Allen, Katja Ehrmann; Barrett, Frederick S; Bogenschutz, Michael P; Carhart-Harris, Robin; Ching, Terence H W; Cosimano, Mary P; Danforth, Alicia; Davis, Alan K; Garcia-Romeu, Albert; Griffiths, Roland; Grob, Charles S; Gründer, Gerhard; Gukasyan, Natalie; Heinzerling, Keith G; Hendricks, Peter S; Holze, Friederike; Horton, David M; Johnson, Matthew W; Kelmendi, Benjamin; Knatz Peck, Stephanie; Koslowski, Michael; Liechti, Matthias E; Mertens, Lea J; Moreno, Francisco A; Nayak, Sandeep M; Nicholas, Christopher R; Preller, Katrin H; Rieser, Nathalie M; Ross, Stephen; Sergi, Karina; Sloshower, Jordan; Smigielski, Lukasz; Stenbæk, Dea Siggaard; Vollenweider, Franz X; Weiss, Brandon; Wolff, Max; Yaden, Mary Elizabeth
INTRODUCTION/UNASSIGNED:Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information-but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes. METHODS/UNASSIGNED:To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents. RESULTS/UNASSIGNED:While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. CONCLUSIONS/UNASSIGNED:Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.
PMCID:12060849
PMID: 40351554
ISSN: 2831-4433
CID: 5843892

A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs

Bogenschutz, Michael P
PMID: 39129581
ISSN: 1360-0443
CID: 5726532

Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities

Krawczyk, Noa; Miller, Megan; Gu, Emma Yuanqi; Irvine, Natalia; Ramirez, Elisbel; Santaella-Tenorio, Julian; Lippincott, Thomas; Bogenschutz, Michael; Bunting, Amanda M; Meacham, Meredith C
BACKGROUND AND AIMS/OBJECTIVE:The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these experiences are perceived to impact opioid use and what these lessons imply for future research and practice. METHODS:We conducted a qualitative study using the Reddit online community platform. We extracted posts that contained key psychedelic terms from the two most subscribed-to subreddits dedicated to discussions of OUD treatment (r/OpiatesRecovery and r/Methadone) from 2018 to 2021. We thematically analyzed content from 151 relevant posts and their respective comments. RESULTS:Two prominent themes identified in discussions were perspectives on the effectiveness of psychedelics in treating OUD, and mechanisms through which psychedelics were thought to impact use and desire to use opioids. For many, psychedelics were deemed to have a strong impact on opioid use via multiple mechanisms, including alleviating physical symptoms of dependence, shifting motivations around desire to use opioids and addressing underlying mental health problems and reasons for use. Others saw the potential promise around psychedelics as exaggerated, acknowledging many people eventually return to use, or even considered psychedelics dangerous. CONCLUSIONS:There appear to be diverse perspectives on the effects of using psychedelics to treat opioid use disorder and an urgent need for controlled studies to better understand the impact of different psychedelics on opioid use, how they may be used in the context of existing treatments and what strategies they must be combined with to ensure safety and effectiveness. Integrating the experiences of people who use drugs will help guide psychedelics research toward effective person-centered interventions to enhance health and wellness.
PMID: 39821493
ISSN: 1360-0443
CID: 5777432

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial

Pagni, Broc A; Zeifman, Richard J; Mennenga, Sarah E; Carrithers, Brennan M; Goldway, Noam; Bhatt, Snehal; O'Donnell, Kelley C; Ross, Stephen; Bogenschutz, Michael P
OBJECTIVE/UNASSIGNED:Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking. METHODS/UNASSIGNED:Eighty-four adults with AUD were randomized to two medication sessions of either psilocybin (N=44) or active placebo (diphenhydramine; N=40), received 12 weekly psychotherapy sessions, and completed follow-up for an additional 24 weeks. Changes in personality traits (week 36 vs. baseline) were assessed with the revised NEO Personality Inventory; daily alcohol consumption was quantified using the timeline followback. RESULTS/UNASSIGNED:Relative to the placebo group, the psilocybin group showed significant reductions in neuroticism and increases in extraversion and openness. Secondary analyses showed that reductions in neuroticism were driven by decreases in the facets depression, impulsiveness, and vulnerability; increases in openness were driven by increases in the facets openness toward feelings and fantasy. Across all participants, decreases in impulsiveness were associated with lower posttreatment alcohol consumption, and an exploratory analysis revealed that these associations were strongest among psilocybin-treated participants who continued moderate- or high-risk drinking prior to the first medication session. CONCLUSIONS/UNASSIGNED:PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.
PMID: 39741446
ISSN: 1535-7228
CID: 5779242

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Mitchell, Jennifer M; Ot'alora G, Marcela; van der Kolk, Bessel; Shannon, Scott; Bogenschutz, Michael; Gelfand, Yevgeniy; Paleos, Casey; Nicholas, Christopher R; Quevedo, Sylvestre; Balliett, Brooke; Hamilton, Scott; Mithoefer, Michael; Kleiman, Sarah; Parker-Guilbert, Kelly; Tzarfaty, Keren; Harrison, Charlotte; de Boer, Alberdina; Doblin, Rick; Yazar-Klosinski, Berra; ,
PMID: 39375459
ISSN: 1546-170x
CID: 5705952

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer

Petridis, Petros D.; Grinband, Jack; Agin-Liebes, Gabrielle; Kinslow, Connor J.; Zeifman, Richard J.; Bogenschutz, Michael P.; Griffiths, Roland R.; Ross, Stephen
ORIGINAL:0017662
ISSN: 2731-6076
CID: 5835022

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study

Pagni, B A; Petridis, P D; Podrebarac, S K; Grinband, J; Claus, E D; Bogenschutz, M P
This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven adult patients completed task-based blood oxygen dependent functional magnetic resonance imaging (fMRI) approximately 3 days before and 2 days after receiving 25 mg of psilocybin (n = 5) or 50 mg of diphenhydramine (n = 6). Visual alcohol and emotionally valanced (positive, negative, or neutral) stimuli were presented in block design. Across both alcohol and emotional cues, psilocybin increased activity in the medial and lateral prefrontal cortex (PFC) and left caudate, and decreased activity in the insular, motor, temporal, parietal, and occipital cortices, and cerebellum. Unique to negative cues, psilocybin increased supramarginal gyrus activity; unique to positive cues, psilocybin increased right hippocampus activity and decreased left hippocampus activity. Greater PFC and caudate engagement and concomitant insula, motor, and cerebellar disengagement suggests enhanced goal-directed action, improved emotional regulation, and diminished craving. The robust changes in brain activity observed in this pilot study warrant larger neuroimaging studies to elucidate neural mechanisms of PAT.Trial registration: NCT02061293.
PMCID:10850478
PMID: 38326432
ISSN: 2045-2322
CID: 5632302

Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis

Agin-Liebes, Gabrielle; Nielson, Elizabeth M; Zingman, Michael; Kim, Katherine; Haas, Alexandra; Owens, Lindsey T; Rogers, Ursula; Bogenschutz, Michael
OBJECTIVE:The primary aim of this qualitative study was to delineate psychological mechanisms of change in the first randomized controlled trial of psilocybin-assisted psychotherapy to treat alcohol use disorder (AUD). Theories regarding psychological processes involved in psychedelic therapy remain underdeveloped. METHOD/METHODS:Participants (N = 13) mostly identified as non-Hispanic and White, with approximately equal proportions of cisgender men and women. Participants engaged in semistructured interviews about their subjective experiences in the study. Questions probed the nature of participants' drinking before and after the study as well as coping patterns in response to strong emotions, stress, and cravings for alcohol. Verbatim transcripts were coded using Dedoose software, and content was analyzed with interpretive phenomenological analysis. RESULTS:Participants reported that the psilocybin treatment helped them process emotions related to painful past events and helped promote states of self-compassion, self-awareness, and feelings of interconnectedness. The acute states during the psilocybin sessions were described as laying the foundation for developing more self-compassionate regulation of negative affect. Participants also described newfound feelings of belonging and an improved quality of relationships following the treatment. CONCLUSION/CONCLUSIONS:Our results support the assertion that psilocybin increases the malleability of self-related processing, and diminishes shame-based and self-critical thought patterns while improving affect regulation and reducing alcohol cravings. These findings suggest that psychosocial treatments that integrate self-compassion training with psychedelic therapy may serve as a useful tool for enhancing psychological outcomes in the treatment of AUD. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
PMCID:10696130
PMID: 37276086
ISSN: 1939-1501
CID: 5610962

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy [Letter]

O'Donnell, Kelley C; Anderson, Brian T; Barrett, Frederick S; Bogenschutz, Michael P; Grob, Charles S; Hendricks, Peter S; Kelmendi, Benjamin; Nayak, Sandeep M; Nicholas, Christopher R; Paleos, Casey A; Stauffer, Christopher S; Gukasyan, Natalie
PMID: 38161295
ISSN: 1535-7228
CID: 5625852